Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors and hydrochlorothiazide both reduced muscle sympathetic nerve activity. Empagliflozin also ...

Background The discovery of sodium-glucose co-transporter 2 (SGLT2) inhibitors, with a novel mechanism independent of insulin secretion or sensitization, bring about a new therapeutic approach to the ...

MADRID —– SGLT2 inhibitors can be added to the list of guideline-directed medical therapies for heart failure that are best initiated before hospital discharge, according to a meta-analysis of ...

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the ...

This article describes the trajectory of adherence patterns among users of sodium-glucose cotransporter 2 (SGLT2) inhibitors. The authors found that baseline factors were unable to predict the ...

Please provide your email address to receive an email when new articles are posted on . Treatment with SGLT2 inhibitors was associated with decreased mortality but increased incidence of lupus ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In adults with ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...